SCHEMBL3205350

SCHEMBL3205350

COC(=O)[C@H](O)c1ccc(O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.56
ESR2 Q92731 2/20 0.56
HIF1A Q16665 2/20 0.49
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP13 P45452 1/20 0.46
KMT2A Q03164 1/20 0.44
PDCD1 Q15116 1/20 0.43
CD274 Q9NZQ7 1/20 0.43
MIF P14174 3/20 0.42
ALDH1A1 P00352 1/20 0.42
HTR1A P08908 1/20 0.42
THPO P40225 1/20 0.42
BLM P54132 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012929 1.00 ESR1 (0.56) ESR1ESR2HIF1ACA12CA1
SCHEMBL3226833 1.00 ESR1 (0.56) ESR1ESR2HIF1ACA12CA1
Ammonia Solution, Strong SCHEMBL7529377 0.98 ESR1 (0.54) ESR1ESR2HIF1ACA12CA1
SCHEMBL9000849 0.83 L3MBTL1 (0.47) ESR1ESR2HIF1AKMT2AALDH1A1
SCHEMBL8594247 0.83 TDP1 (0.47) ESR1ESR2KMT2AALDH1A1TDP1
SCHEMBL8594253 0.83 TDP1 (0.47) ESR1ESR2KMT2AALDH1A1TDP1
SCHEMBL9000860 0.83 L3MBTL1 (0.47) ESR1ESR2HIF1AKMT2AALDH1A1
SCHEMBL1564925 0.82 CYP1A2 (0.50) KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL1566235 0.82 HDAC3 (0.46) CA12CA7CA9CA14KMT2A
SCHEMBL8592635 0.82 SLC6A3 (0.47) ESR1ESR2KMT2AALDH1A1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-62263087-A None JP disclosed
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2026-02-05 US disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 US disclosed
US-12458653-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-11-04 US disclosed
US-12427176-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2025-09-30 US disclosed
US-12303488-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-05-20 US disclosed
EP-4417252-A2 CANNABIS BASED THERAPEUTIC AND METHOD OF USE Yuzu LV LLC (US) 2024-08-21 EP disclosed
US-20240216457-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 US disclosed
US-20240216456-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 US disclosed
US-20240207342-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-06-27 US disclosed
US-20210023044-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2021-01-28 US disclosed
EP-2077987-B1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF TRANSTECH PHARMA INC (US) 2010-11-24 EP disclosed
US-20100036150-A1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF TRANSTECH PHARMA, INC. 2010-02-11 US disclosed
US-20100036150-A1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF TRANSTECH PHARMA, INC. 2010-02-11 US disclosed
US-20100036150-A1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF TRANSTECH PHARMA, INC. 2010-02-11 US disclosed
EP-2077987-A1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF Transtech Pharma, Inc. (US) 2009-07-15 EP disclosed
WO-2008051563-A1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF TRANSTECH PHARMA, INC. (US) 2008-05-02 WO disclosed
WO-2008051563-A1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF TRANSTECH PHARMA, INC. (US) 2008-05-02 WO disclosed
EP-0816316-A1 PROCESS FOR PRODUCING 1,2-ETHANEDIOL DERIVATIVES NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1998-01-07 EP disclosed
JP-S62263087-A THERMAL RECORDING MATERIAL NIPPON SYNTHETIC CHEM IND CO LTD:THE 1987-11-16 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 ESR1 3160/4885ESR2 2308/4885HIF1A 1370/4885
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS TRPV1, SOST, RUNX1 ESR1 1617/4885ESR2 1839/4885HIF1A 850/4885
US-20100036150-A1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF CYP8B1, CYP51A1, COMT ESR1 1977/4885ESR2 3266/4885HIF1A 684/4885
US-20210023044-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR2, CNR1, OPRK1 ESR1 3529/4885ESR2 3269/4885HIF1A 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.